Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD (clinicaltrials.gov) - Sep 1, 2026 - P=N/A | N=170 | Recruiting | Sponsor: First Affiliated Hospital of Zhejiang University
New trial • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Transplantation
|